Concepedia

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

Angela Alistar, Bonny Morris, Rodwige Desnoyer, Heidi D. Klepin, Keyanoosh Hosseinzadeh, Clancy J. Clark, A. L. Cameron, John R. Leyendecker, Ralph B. D’Agostino, Ümit Topaloĝlu,

The Lancet Oncology · 2017 · 228 citations · 14 references

DOI

Concepts

References

14

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

SEER Cancer Statistics Review, 1975-2003

Lynn A. G. Ries, D. Harkins, Martin Krapcho et al. · ScholarWorks - Georgia State University (Georgia State University) · 2006 · 11.5K citations · Full text

, , +12

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

, , +13

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations

, , +13

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

Zuzana Zachar, James F. Marecek, Claudia Maturo et al. · Journal of Molecular Medicine · 2011 · 220 citations

, , +12